Anbio Biotechnology
NNNN
10 hedge funds and large institutions have $2.54M invested in Anbio Biotechnology in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
172% more capital invested
Capital invested by funds: $937K → $2.54M (+$1.61M)
100% more funds holding
Funds holding: 5 → 10 (+5)
0.09% more ownership
Funds ownership: 0.07% → 0.16% (+0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$469K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$388K |
| 3 |
Morgan Stanley
New York
|
+$369K |
| 4 |
Millennium Management
New York
|
+$318K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$310K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$437K |
NNNN Hedge Fund Activity: Q3 2025 in Review
10 of the 7,643 institutional investors tracked by Wall St. Rank reported a position in Anbio Biotechnology (NNNN) for Q3 2025, worth a combined $2.54M — up 172% from $937K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NNNN positions and 0 closed out — a net gain of 5 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $469K. The largest seller was UBS Group, cutting an estimated $437K.
- 10 institutional investors held Anbio Biotechnology (NNNN) as of Q3 2025, up from 5 in Q2 2025.
- Funds reported $2.54M of Anbio Biotechnology stock for Q3 2025, up 172% quarter-over-quarter.
- 5 funds opened new Anbio Biotechnology positions in Q3 2025 and 0 closed out, a net change of +5 holders.
- The largest Anbio Biotechnology buyer in Q3 2025 was Marshall Wace, an estimated $469K added.
- The largest Anbio Biotechnology seller in Q3 2025 was UBS Group, an estimated $437K sold.
Based on aggregated 13F filings for Q3 2025.